Steven H. Ferris
YOU?
Author Swipe
View article: Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies<i>LRRC4C, LHX5-AS1</i>and nominates ancestry-specific loci<i>PTPRK</i>,<i>GRB14</i>, and<i>KIAA0825</i>as novel risk loci for Alzheimer’s disease: the Alzheimer’s Disease Genetics Consortium
Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies<i>LRRC4C, LHX5-AS1</i>and nominates ancestry-specific loci<i>PTPRK</i>,<i>GRB14</i>, and<i>KIAA0825</i>as novel risk loci for Alzheimer’s disease: the Alzheimer’s Disease Genetics Consortium Open
Limited ancestral diversity has impaired our ability to detect risk variants more prevalent in non-European ancestry groups in genome-wide association studies (GWAS). We constructed and analyzed a multi-ancestry GWAS dataset in the Alzheim…
View article: Manifestations of Alzheimer’s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90
Manifestations of Alzheimer’s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90 Open
Genetics play an important role in late-onset Alzheimer’s Disease (AD) etiology and dozens of genetic variants have been implicated in AD risk through large-scale GWAS meta-analyses. However, the precise mechanistic effects of most of thes…
View article: The cognitive syndrome of vascular dementia: implications for clinical trials
The cognitive syndrome of vascular dementia: implications for clinical trials Open
Dementia is common among patients with cerebrovascular disease, particularly in a setting of one or more clinically evident strokes. Prior cohort and case studies have suggested that the cognitive syndrome of vascular dementia is character…
View article: Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel Open
While the major pathways involved in Alzheimer disease etiology in African American individuals are similar to those in non-Hispanic White individuals, the disease-associated loci within these pathways differ.
View article: Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS)
Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS) Open
Introduction: The neuropsychological battery of the Uniform Data Set (UDSNB) was implemented in 2005 by the National Institute on Aging (NIA) Alzheimer Disease Centers program to measure cognitive performance in dementia and mild cognitive…
View article: The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults
The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults Open
Background: Subjective cognitive complaint is a sensitive marker of decline. Objective: This study aimed to (1) examine reliability of subjective cognitive complaint using the Cognitive Function Instrument (CFI), and (2) assess the utility…
View article: Transethnic genome‐wide scan identifies novel Alzheimer's disease loci
Transethnic genome‐wide scan identifies novel Alzheimer's disease loci Open
Introduction Genetic loci for Alzheimer's disease (AD) have been identified in whites of European ancestry, but the genetic architecture of AD among other populations is less understood. Methods We conducted a transethnic genome‐wide assoc…
View article: <i>ABCA7</i> frameshift deletion associated with Alzheimer disease in African Americans
<i>ABCA7</i> frameshift deletion associated with Alzheimer disease in African Americans Open
This common ABCA7 deletion could represent an ethnic-specific pathogenic alteration in AD.
View article: Assessment of the genetic variance of late-onset Alzheimer's disease
Assessment of the genetic variance of late-onset Alzheimer's disease Open
Alzheimer's disease (AD) is a complex genetic disorder with no effective treatments. More than 20 common markers have been identified, which are associated with AD. Recently, several rare variants have been identified in Amyloid Precursor …
View article: Targeting Prodromal Alzheimer Disease With Avagacestat
Targeting Prodromal Alzheimer Disease With Avagacestat Open
clinicaltrials.gov Identifier: NCT00890890.
View article: Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals
Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals Open
To our knowledge, we discovered the first evidence of increased burden of ROHs among patients with AD from an outbred African American population, which could reflect either the cumulative effect of multiple ROHs to AD or the contribution …
View article: Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer’s Disease
Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer’s Disease Open
Severe Impairment Battery (SIB) data from the 24-week, randomized, double-blind ACTivities of daily living and cognitION (ACTION) study suggest that patients with severe Alzheimer’s disease (AD) benefit from treatment with 13.3 versus 4.6 …
View article: A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease Open
This study provides Class II evidence that for patients with AD resveratrol is safe, well-tolerated, and alters some AD biomarker trajectories. The study is rated Class II because more than 2 primary outcomes were designated.
View article: Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials Open
The (11)C-PiB-PET imaging results demonstrated reduction of fibrillar Aβ accumulation in patients with Alzheimer disease treated with bapineuzumab; however, as no clinical benefit was observed, the findings are consistent with the hypothes…
View article: Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia
Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia Open
Demonstrating long-term clinical benefit will be critical for the success of recently launched secondary prevention trials. The CFI appears to be a brief, but informative potential outcome measure that provides insight into functional abil…